{"ATC Code":"G04CB01","Abbreviation":"","Aliases":["Proscar","Propecia","Finastid","Prostide","Chibro-Proscar","MK-906","Finasterida","Finpecia","Finasteridum","MK 906"],"Biological Half-Life":"In healthy young subjects receiving finasteride, the mean elimination half-life in plasma was 6 hours ranging from 3 to 16 hours. In elderly patients over the age of 70 years, the half-life is prolonged to 8 hours.","CAS":"98319-26-7","ChEBI":"CHEBI:5062","ChEMBL":"CHEMBL710","ChemicalClasses":["steroid"],"Chirality":"absolute","Color/Form":"White to off-white crystalline solid","Dosing Info":[],"Drug Classes":"Benign Prostatic Hypertrophy Agents","Drug Indication":"Finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. A combination product with [tadalafil] is also used for the symptomatic treatment of BPH for up to 26 weeks.  Finasteride is also indicated for the treatment of male pattern hair loss (androgenetic alopecia, hereditary alopecia, or common male baldness) in male patients.","DrugClasses":[],"European Community (EC) Number":"620-534-3","FDA Pharmacological Classification":"57GNO57U7G","Human Drugs":"Human drug -\u003e Prescription","IUPACName":"(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide","Impurities":["dutasteride methyl ester",".delta.5-finasteride","dihydrofinasteride"],"InChI":"InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1","InChIKey":"DBEPLOCGEIEOCV-WSBQPABSSA-N","MeSH Pharmacological Classification":"Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE. (See all compounds classified as 5-alpha Reductase Inhibitors.)","Melting Point":"252-254 °C","MolecularFormula":"C\u003csub\u003e23\u003c/sub\u003eH\u003csub\u003e36\u003c/sub\u003eN\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"372.5 g/mol","Opticalactivity":"UNSPECIFIED","Pharmacodynamics":"Finasteride is an antiandrogenic compound that works by suppressing the production of serum and intraprostatic dihydrotestosterone (DHT) in men via inhibiting the enzyme responsible for the biosynthesis of DHT. The maximum effect of a rapid reduction in serum DHT concentration is expected to be observed 8 hours following administration of the first dose. In a single man receiving a single oral dose of 5 mg finasteride for up to 4 years, there was a reduction in the serum DHT concentrations by approximately 70% and the median circulating level of testosterone increased by approximately 10-20% within the physiologic range. In a double-blind, placebo-controlled study, finasteride reduced intraprostatic DHT level by 91.4% but finasteride is not expected to decrease the DHT levels to castrate levels since circulating testosterone is also converted to DHT by the type 1 isoenzyme expressed in other tissues. It is expected that DHT levels return to normal within 14 days upon discontinuation of the drug. In a study of male patients with benign prostatic hyperplasia prior to prostatectomy, the treatment with finasteride resulted in an approximate 80% lower DHT content was measured in prostatic tissue removed at surgery compared to placebo. While finasteride reduces the size of the prostate gland by 20%, this may not correlate well with improvement in symptoms. The effects of finasteride are reported to be more pronounced in male patients with enlarged prostates (\u003e25 mL) who are at the greatest risk of disease progression.  In phase III clinical studies, oral administration of finasteride in male patients with male pattern hair loss promoted hair growth and prevented further hair loss by 66% and 83% of the subjects, respectively, which lasted during two years' treatment. The incidences of these effects in treatment groups were significantly higher than that of the group receiving a placebo. Following finasteride administration, the levels of DHT in the scalp skin was shown to be reduced by more than 60%, indicating that the DHT found in scalp is derived from both local DHT production and circulating DHT. The effect of finasteride on scalp DHT is likely seen because of its effect on both local follicular DHT levels as well as serum DHT levels.. There is evidence from early clinical observations and controlled studies that finasteride may reduce bleeding of prostatic origin.","Physical Description":"Solid","PubChemId":57363,"Record Description":["Finasteride is an aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia. It has a role as an androgen antagonist, an EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor and an antihyperplasia drug. It is an aza-steroid, a 3-oxo steroid and a delta-lactam. It derives from a hydride of a 5alpha-androstane.","Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or the need for surgical procedures. In 1998, it was approved by the FDA to treat male pattern hair loss. Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo or in combination with [doxazosin], an alpha-blocker.  Both benign prostatic hyperplasia and androgenic alopecia are androgen-dependent disorders that are characterized by in situ high levels of DHT. In the treatment of benign prostate hyperplasia, alpha-blockers such as [tamsulosin] and [terazosin] are also used. Compared to alpha-blockers that focus on providing the rapid relief of symptoms, 5α-reductase inhibitors aim to target the underlying disease by blocking the effects of the primary androgen involved in benign prostate hyperplasia and androgenic alopecia, thus reducing the risk for secondary complications while providing symptom control.","Finasteride is a 5-alpha Reductase Inhibitor. The mechanism of action of finasteride is as a 5-alpha Reductase Inhibitor.","Finasteride is a 5-alpha reductase inhibitor used to treat symptoms of benign prostatic hypertrophy and male pattern baldness. Finasteride is associated with a low rate of transient serum aminotransferase elevations, but has yet to be linked to instances of clinically apparent, acute liver injury.","Finasteride is a synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.","FINASTERIDE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 6 approved and 6 investigational indications.","An orally active testosterone 5-alpha-reductase inhibitor. It is used as a surgical alternative for treatment of benign prostatic hyperplasia. ","An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.","See also: Finasteride; tadalafil (component of); Finasteride; minoxidil (component of); Alfatradiol; finasteride; minoxidil sulfate ester (component of) ... View More ...","Finasteride is an aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia. It has a role as an androgen antagonist, an EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor and an antihyperplasia drug. It is an aza-steroid, a 3-oxo steroid and a delta-lactam. It derives from a hydride of a 5alpha-androstane.","LiverTox|Urologic|Prostatic hypertrophy|5 alpha reductase inhibitor"],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Finasteride"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q424167"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB01216"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/57363"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.51714.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL710"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5062"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=98319-26-7"},{"name":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0001984"},{"name":"KEGG","url":"https://www.kegg.jp/entry/D00321"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/57GNO57U7G"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID3020625"}],"SMILES":"C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C","Solubility":"52.8 [ug/mL] (The mean of the results at pH 7.4)","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="106.494mm" version="1.2" viewBox="0 0 136.397 106.494" width="136.397mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="107.0" stroke="none" width="137.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <g class="bond" id="mol1bnd1">
                        
                <line x1="82.362" x2="81.665" y1="54.167" y2="54.241"/>
                        
                <line x1="82.92" x2="81.644" y1="56.662" y2="56.798"/>
                        
                <line x1="83.479" x2="81.623" y1="59.157" y2="59.354"/>
                        
                <line x1="84.038" x2="81.602" y1="61.651" y2="61.911"/>
                        
                <line x1="84.597" x2="81.58" y1="64.146" y2="64.467"/>
                        
                <line x1="85.156" x2="81.559" y1="66.641" y2="67.024"/>
                        
                <line x1="85.715" x2="81.538" y1="69.136" y2="69.581"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd2" x1="82.013" x2="68.805" y1="54.204" y2="61.824"/>
                  
            <line class="bond" id="mol1bnd3" x1="68.805" x2="55.597" y1="61.824" y2="54.204"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="55.901" x2="55.294" y1="39.139" y2="38.789"/>
                        
                <line x1="56.153" x2="55.042" y1="41.825" y2="41.183"/>
                        
                <line x1="56.406" x2="54.789" y1="44.51" y2="43.577"/>
                        
                <line x1="56.659" x2="54.536" y1="47.196" y2="45.972"/>
                        
                <line x1="56.911" x2="54.284" y1="49.882" y2="48.366"/>
                        
                <line x1="57.164" x2="54.031" y1="52.568" y2="50.76"/>
                        
                <line x1="57.417" x2="53.778" y1="55.253" y2="53.154"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="55.597" x2="68.805" y1="38.964" y2="31.344"/>
                  
            <line class="bond" id="mol1bnd6" x1="68.805" x2="82.013" y1="31.344" y2="38.964"/>
                  
            <line class="bond" id="mol1bnd7" x1="82.013" x2="82.013" y1="54.204" y2="38.964"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="82.219" x2="81.808" y1="39.247" y2="38.681"/>
                        
                <line x1="84.442" x2="83.736" y1="38.782" y2="37.811"/>
                        
                <line x1="86.665" x2="85.665" y1="38.316" y2="36.941"/>
                        
                <line x1="88.887" x2="87.593" y1="37.851" y2="36.071"/>
                        
                <line x1="91.11" x2="89.522" y1="37.385" y2="35.201"/>
                        
                <line x1="93.332" x2="91.45" y1="36.92" y2="34.331"/>
                        
                <line x1="95.555" x2="93.378" y1="36.454" y2="33.462"/>
                        
                <line x1="97.778" x2="95.307" y1="35.989" y2="32.592"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="96.542" x2="105.483" y1="34.29" y2="46.584"/>
                  
            <line class="bond" id="mol1bnd10" x1="105.483" x2="96.542" y1="46.584" y2="58.878"/>
                  
            <line class="bond" id="mol1bnd11" x1="82.013" x2="96.542" y1="54.204" y2="58.878"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="96.875" x2="96.209" y1="58.769" y2="58.986"/>
                        
                <line x1="97.94" x2="96.72" y1="61.093" y2="61.491"/>
                        
                <line x1="99.005" x2="97.231" y1="63.417" y2="63.996"/>
                        
                <line x1="100.071" x2="97.741" y1="65.742" y2="66.502"/>
                        
                <line x1="101.136" x2="98.252" y1="68.066" y2="69.007"/>
                        
                <line x1="102.201" x2="98.762" y1="70.39" y2="71.512"/>
                        
                <line x1="103.266" x2="99.273" y1="72.714" y2="74.017"/>
                      
            </g>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="101.269" x2="93.74" y1="73.366" y2="81.748"/>
                        
                <line x1="102.143" x2="95.554" y1="76.043" y2="83.378"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="93.74" x2="97.50450000000001" y1="81.748" y2="77.557"/>
                <line class="hi" stroke="#FF0D0D" x1="95.554" x2="98.8485" y1="83.378" y2="79.7105"/>
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="101.269" x2="112.87" y1="73.366" y2="75.817"/>
                  
            <line class="bond" id="mol1bnd15" x1="117.414" x2="120.908" y1="80.297" y2="91.004"/>
                  
            <line class="bond" id="mol1bnd16" x1="120.908" x2="106.419" y1="91.004" y2="95.732"/>
                  
            <line class="bond" id="mol1bnd17" x1="120.908" x2="125.635" y1="91.004" y2="105.493"/>
                  
            <line class="bond" id="mol1bnd18" x1="120.908" x2="135.396" y1="91.004" y2="86.277"/>
                  
            <path class="bond" d="M68.455 31.344h.701l1.619 -14.506l-1.969 -1.138l-2.25 -1.3z" fill="#000000" id="mol1bnd19" stroke="none"/>
                  
            <line class="bond" id="mol1bnd20" x1="68.806" x2="55.61" y1="16.104" y2="8.482"/>
                  
            <line class="bond" id="mol1bnd21" x1="55.61" x2="42.411" y1="8.482" y2="16.097"/>
                  
            <line class="bond" id="mol1bnd22" x1="42.411" x2="42.404" y1="16.097" y2="31.336"/>
                  
            <line class="bond" id="mol1bnd23" x1="55.597" x2="42.404" y1="38.964" y2="31.336"/>
                  
            <line class="bond" id="mol1bnd24" x1="42.404" x2="29.203" y1="31.336" y2="38.951"/>
                  
            <g class="bond" id="mol1bnd25">
                        
                <line x1="16.008" x2="29.203" y1="31.325" y2="38.951"/>
                        
                <line x1="18.447" x2="29.204" y1="29.919" y2="36.135"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd26" x1="16.008" x2="16.014" y1="31.325" y2="16.085"/>
                  
            <g class="bond" id="mol1bnd27">
                        
                <line x1="16.014" x2="5.484" y1="17.493" y2="11.408"/>
                        
                <line x1="17.234" x2="6.704" y1="15.382" y2="9.297"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="5.484" x2="10.748999999999999" y1="11.408" y2="14.450499999999998"/>
                <line class="hi" stroke="#FF0D0D" x1="6.704000000000001" x2="11.969000000000001" y1="9.297" y2="12.339500000000001"/>
            </g>
                  
            <line class="bond" id="mol1bnd28" x1="16.014" x2="26.062" y1="16.085" y2="10.29"/>
                  
            <g class="bond" id="mol1bnd29">
                        
                <line stroke="#000000" x1="42.235" x2="42.586" y1="16.4" y2="15.794"/>
                        
                <line stroke="#3050F8" x1="40.225" x2="40.826" y1="15.527" y2="14.488"/>
                        
                <line stroke="#3050F8" x1="38.215" x2="39.066" y1="14.654" y2="13.182"/>
                        
                <line stroke="#3050F8" x1="36.205" x2="37.306" y1="13.781" y2="11.876"/>
                        
                <line stroke="#3050F8" x1="34.195" x2="35.546" y1="12.908" y2="10.57"/>
                        
                <line stroke="#3050F8" x1="32.185" x2="33.787" y1="12.035" y2="9.264"/>
                      
            </g>
                  
            <g class="bond" id="mol1bnd30">
                        
                <line x1="42.754" x2="42.054" y1="31.336" y2="31.335"/>
                        
                <line x1="43.003" x2="41.803" y1="33.513" y2="33.513"/>
                        
                <line x1="43.252" x2="41.552" y1="35.69" y2="35.69"/>
                        
                <line x1="43.501" x2="41.301" y1="37.868" y2="37.867"/>
                        
                <line x1="43.75" x2="41.05" y1="40.045" y2="40.044"/>
                        
                <line x1="43.999" x2="40.799" y1="42.222" y2="42.221"/>
                        
                <line x1="44.248" x2="40.547" y1="44.399" y2="44.398"/>
                        
                <line x1="44.497" x2="40.296" y1="46.577" y2="46.575"/>
                      
            </g>
                  
            <path class="atom" d="M94.252 85.516q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .566 .256 1.328zM90.389 85.516q-.0 .922 .386 1.458q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.392 .524 -.392 1.453z" fill="#FF0D0D" id="mol1atm12" stroke="none"/>
                  
            <g class="atom" id="mol1atm13">
                        
                <path d="M118.121 78.966h-.72l-2.62 -4.066h-.029q.011 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" stroke="none"/>
                        
                <path d="M122.427 78.966h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M5.078 8.457q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .31 .756 .875q.256 .566 .256 1.328zM1.215 8.457q-.0 .922 .387 1.458q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm25" stroke="none"/>
                  
            <g class="atom" id="mol1atm26">
                        
                <path d="M31.157 10.921h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.578v4.9z" stroke="none"/>
                        
                <path d="M31.02 5.459h-.619v-2.286h-2.513v2.286h-.613v-4.899h.613v2.072h2.513v-2.072h.619v4.899z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="112.87" x2="107.0695" y1="75.817" y2="74.5915"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="117.414" x2="119.161" y1="80.297" y2="85.6505"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="117.50391739255251" x2="119.161" y1="80.5725425077446" y2="85.6505"/>
            <line class="hi" id="mol1bnd28" stroke="#3050F8" x1="26.062" x2="21.038" y1="10.29" y2="13.1875"/>
            <line class="hi" id="mol1bnd28" stroke="#3050F8" x1="26.062" x2="21.038" y1="10.29" y2="13.1875"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Enzyme Inhibitors","Title":"Finasteride","UNII":"57GNO57U7G","Wikidata":"Q424167","XLogP":3}